I'm not saying CCSVI treatment is the be all and end all, but how do we even get a crack at fair results when there's no balance in the panels? Dr. Rubin doesn't study venous diseases, his research is in bioactive phospholipids. I'm not suggesting he's driven by pharmaceutical companies (at all, I swear), but how do we get past the stupid playground politics between vascular professionals looking for MS solutions in body mechanics and molecular researchers looking for MS solutions in drugs. We need both! Don't put someone whose speciality is inflammation in front of the mic when the questions are about CCSVI.